MedScopeGlobal — odborný medicínský magazín

ViaLongeVita

ViaLongeVita

Internal Medicine

From the Czech desk of MedScopeGlobal. Shared with attribution — the local desk added context for this edition.

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trialVIP

Nature Medicine, Published online: 27 August 2026; doi:10.1038/s41591-026-04603-3 In the phase 1 part of the ongoing phase 1/2 COMPARE trial, CD19 CAR T cell treatment of patients with severe, treatment-refractory rheumatoid arthritis was well tolerated with clinical improvement seen in all patients.]]>

From the Czech desk of MedScopeGlobal

27 de agosto de 2026

Salvar

Este conteúdo não é diagnóstico médico nem recomendação de tratamento. Consulte sempre o seu médico ou o SUS.

Illustration for "CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial" — healthy lifestyle, diverse group of adults

Did this article help? Leave a tip — you keep the next reader reading

Nature Medicine, Published online: 27 August 2026; doi:10.1038/s41591-026-04603-3 In the phase 1 part of the ongoing phase 1/2 COMPARE trial, CD19 CAR T cell treatment of patients with severe, treatment-refractory rheumatoid arthritis was well tolerated with clinical improvement seen in all patients.]]>

Pro váš zájem

Tento obsah je součástí MedScope VIP

Na základě vašeho zájmu o medicínu jsme pro vás připravili plný přístup k odborným článkům, alertům a AI asistentovi.

14 dní zkušební verze zdarma — vyzkoušejte bez rizika

Odemknout předplatným

Již máte účet? Přihlásit se · Srovnání tarifů

Support the author (MedScopeGlobal Editorial) · Tip

Optional micro-contribution — like a tip. When you give, the next reader still gets a clear health text.

A tip is not a VIP subscription and does not unlock paid content — it is optional support for the desk.

Contribution

Donate

A micro-donation keeps clear health writing open for the next person.

Leitura relacionada

Public health

Public health

Peso sustentável no Brasil: prato repetível, caminhada, GLP-1 com a UBS

Saúde metabólica para leitores no Brasil — sem dieta milagre. UBS/SUS, SAMU 192, ANVISA. Não SÚKL.

MedScopeGlobal Editorial
Longevity

Longevity

Longevidade: healthspan começa no sono, não no suplemento

A redação brasileira escreve anos em forma — sono, caminhada, UBS.

MedScopeGlobal Editorial
Public health

Public health

Biohacking com evidência: o relógio conta passos, não trata

Sensores para sono e caminhada. Não é diagnóstico. Marco ANVISA.

MedScopeGlobal Editorial

Conteúdo recomendado

Prepared by the MedScopeGlobal.com editorial team — educational health content for the public. Always consult a physician for personal medical decisions.

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial | ViaLongeVita